β-lactamase inhibitor and use thereof

A compound of formula (I), or an ester, a stereoisomer, or a pharmaceutically acceptable salt thereof:

• wherein W1 is selected from an optionally substituted 5- or 6-membered heteroaromatic ring containing O, N, and/or S, and —C(O)—;
• (i) when W1 is the optionally substituted 5- or 6-membered heteroaromatic ring containing O, N, and/or S, W1 is optionally substituted with C1-C12 alkyl,
• W2 is selected from:
• (a) H
• (b)
• wherein R1 is selected from
• R2, R3, R4, R4′, R5, and R6 are each independently selected from H, C1-C12 alkyl, amino C1-C12 alkyl, C1-C12 alkylamino C1-C12 alkyl,
• Ra and Rb are each independently selected from H, C1-C12 alkyl, C3-C8 cycloalkyl, OH, —OC1-C12 alkyl, —NH2, —NHC1-C12 alkyl, —N(C1-C12 alkyl)2, —SH, —SC1-C12 alkyl, —S(O)C1-C12 alkyl, —S(O2)C1-C12 alkyl, and —SO3H;
• R7 and R7′ are each independently selected from —NH2, —NHC1-C12 alkyl, —N(C1-C12 alkyl)2, —OC1-C12 alkyl, and —SC1-C12 alkyl;
• R8 and R8′ are each independently selected from NH, —N(C1-C12 alkyl), O, and S;
• R9 and R9′ are each independently selected from —NH—, —N(C1-C12 alkyl)-, —O—, and —S—;
• Z1 is selected from CR10R11, and NR12;
• R10, R11, and R12 are each independently selected from H, NH2,
• R13 and R15 are each independently selected from —NH2, —NHC1-C12 alkyl, —N(C1-C12 alkyl)2, —OC1-C12 alkyl, and —SC1-C12 alkyl;
• R14 and R16 are each independently selected from NH, NC1-C12 alkyl, O, and S;
• R17 is selected from —NH—, —N(C1-C12 alkyl)-, —O—, and —S—;
• i, j, k, l, m, n, p, q, r, and s are each independently selected from 0, 1, 2, 3, 4, 5, and 6, provided that q and r are not both 0;
• R1′ is selected from H, C1-C12 alkyl, C3-C8 cycloalkyl, OH, —OC1-C12 alkyl, —NH2, —NHC1-C12 alkyl, —N(C1-C12 alkyl)2, —SH, —SC1-C12 alkyl, —S(O)C1-C12 alkyl, —S(O2)C1-C12 alkyl, and —SO3H;
• (c)
• wherein Z2 is selected from CR18R19, and NR20;
• R18, R19 and R20 are each independently selected from H, NH2, and
• R21 is selected from —NH2, —NHC1-C12 alkyl, —N(C1-C12 alkyl)2, —OC1-C12 alkyl, and —SC1-C12 alkyl;
• R22 is selected from NH, NC1-C12 alkyl, O, and S;
• t, u and w are each independently selected from 0, 1, 2, 3, 4, 5, and 6, provided that t and u are not both 0;
• (d)
• wherein Z3 and Z4 are each independently selected from —NR25—, and —O—;
• R23 and R24 are each independently selected from H and C1-C12 alkyl, or R23 and R24 together form ═O or ═NH;
• R25 is selected from H, amino C1-C12 alkyl, and C1-C12 alkylamino C1-C12 alkyl;
• (ii) when W1 is selected from —C(O)—,
• W2 is selected from —OR26 and —NHR27, wherein R26 and R27 are each independently selected from H, C1-C12 alkyl, and
• Z5 is selected from CR28R29, and NR30;
• R28, R29, and R30 are each independently selected from H, NH2, and
• R31 is selected from —NH2, —NHC1-C12 alkyl, —N(C1-C12 alkyl)2, —OC1-C12 alkyl, and —SC1-C12 alkyl;
• R32 is selected from NH, NC1-C12 alkyl, O, and S;
• x, y and z are each independently selected from 0, 1, 2, 3, 4, 5, and 6, provided that x and y are not both 0;
• W3 is selected from —SO3M, —OSO3M, —OSO2NH2, —OPO3M, —OCR33R34CO2M, —OCR35R36SO3M, and —OCR37R38PO3M;
• wherein M is selected from H and a pharmaceutically acceptable cation;
• R33, R34, R35, R36, R37, and R38 are each independently selected from H, C1-C12 alkyl, and halogen.